牛牛AI助理已提取核心訊息
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, completed a sale of 1,913 common shares on February 20, 2024. The transaction was executed at a price of $79.67 per share, resulting in a total market value of $152,408.71. Prior to this sale, Kasinger acquired 3,825 shares through the exercise of derivative securities on February 18, 2024. Following these transactions, Kasinger's direct holdings in CRISPR Therapeutics amount to 57,371 common shares. The sale represents an open market transaction, and the acquisition was a result of exercising options available to Kasinger.
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, completed a sale of 1,913 common shares on February 20, 2024. The transaction was executed at a price of $79.67 per share, resulting in a total market value of $152,408.71. Prior to this sale, Kasinger acquired 3,825 shares through the exercise of derivative securities on February 18, 2024. Following these transactions, Kasinger's direct holdings in CRISPR Therapeutics amount to 57,371 common shares. The sale represents an open market transaction, and the acquisition was a result of exercising options available to Kasinger.
CRISPR Therapeutics總法律顧問兼秘書詹姆斯·卡辛格於2024年2月20日完成了1,913股普通股的出售。該交易以每股79.67美元的價格執行，總市值爲152,408.71美元。在此次出售之前，卡辛格於2024年2月18日通過行使衍生證券收購了3,825股股票。這些交易之後，卡辛格在CRISPR Therapeutics的直接持有量爲57,371股普通股。此次出售是一項公開市場交易，此次收購是行使Kasinger可用期權的結果。
CRISPR Therapeutics總法律顧問兼秘書詹姆斯·卡辛格於2024年2月20日完成了1,913股普通股的出售。該交易以每股79.67美元的價格執行，總市值爲152,408.71美元。在此次出售之前，卡辛格於2024年2月18日通過行使衍生證券收購了3,825股股票。這些交易之後，卡辛格在CRISPR Therapeutics的直接持有量爲57,371股普通股。此次出售是一項公開市場交易，此次收購是行使Kasinger可用期權的結果。
有用
沒用